<DOC>
	<DOCNO>NCT00473551</DOCNO>
	<brief_summary>Primary Objective : 1 . To determine maximally tolerate dose anti-third party cytolytic T-lymphocytes , define dose achieve engraftment without severe GVHD ( graft-vs-host disease ) 90 day allogeneic transplantation CD34+ hematopoietic progenitor cell . Secondary Objective : 1 . Toxicity , response rate , time progression overall survival .</brief_summary>
	<brief_title>Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation Indolent Lymphoid Malignancies</brief_title>
	<detailed_description>GVHD major problem stem cell transplantation healthy donor . It cause T-lymphocytes ( type immune cell ) donor react badly person receive transplant ( recipient ) . Researchers want see stimulate donor T-lymphocytes another person ( third party ) grow 28 day decrease chance develop GVHD . If find eligible take part study , receive treatment , include chemotherapy radiation , stem cell transplantation . These include rituximab , cyclophosphamide , fludarabine , mesna . Rituximab design attach lymphoma cell , cause die . Cyclophosphamide design destroy cancer cell interfere multiplication slow stop growth spread throughout body . Fludarabine design interfere DNA repair enzymes leukemic cell repair damage DNA . This increase likelihood cell die . Mesna drug lower risk bladder side effect cyclophosphamide . Total body radiation give reduce risk transplant rejection . Participants CLL lymphoma receive Rituxan ( rituximab ) vein , give several hour dose . The first rituximab dose 13 day transplant . This follow 3 dos rituximab , give 6 day transplant , 1 8 day transplant . All participant receive fludarabine vein 30 minute per day 4 day , start 6 day transplant . All participant also receive cyclophosphamide vein 2 hour . The cyclophosphamide give immediately first dose fludarabine . All participant also receive continuous infusion mesna vein 24 hour receive cyclophosphamide . One day transplantation , total body radiation . After receive total body radiation , receive stem cell transplantation . On day transplant , receive anti-third party T Lymphocytes ( CTLs ) vein . This follow vein infusion stem cell donor . A sample anti-third party T-cells cell also test immune function . All participant receive sirolimus mouth 10 day , start 2 day transplantation . Sirolimus immunosuppressive drug give reduce risk transplant rejection . You remain hospital 4 week transplant . You continue outpatient Houston area 100 day transplantation , doctor feel okay leave Houston area . If disease get bad transplantation , may receive additional immune cell donor ( DLI-donor lymphocyte infusion ) .You may take study transplant grow reject , enough CTLs produce , disease continue get bad receive additional donor cell , experience intolerable side effect . You frequent blood test medically necessary evaluate medical condition . About 3 tablespoon blood collect immune function test 1 , 2 , 3 , 6 12 month transplant . You bone marrow biopsy , x-rays , CT scan evaluation cancer 1 , 3 , 6 , 9 , 12 month transplant . The study 1 year . You followed-up time routine care , doctor feel necessary . This investigational study . All drug use study , approve FDA treatment cancer transplantation . The Miltenyi CliniMACS System use purify stem cell anti-third party CTLs approve FDA , use study experimental . Up 24 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Age 1870 Confirmed diagnosis follicular lymphoma , mantle cell lymphoma , chronic lymphocyte leukemia/small lymphocytic lymphoma multiple myeloma . Patients must persistent progressive disease despite initial chemotherapy . Patients must achieve partial complete response recent chemotherapy . Patients must human leukocyte antigen ( HLA ) match ( HLAA , B , C DR DQ ) relate donor seropositive Epstein Barr virus capable donate peripheral blood mononuclear cell peripheral blood progenitor cell . Patient must HLA completely mismatch HLA class I loci ( A , B C ) 3rd party stimulator cell . HLAA ( 330301 , 310102 ) HLAB ( 5801,150101 [ 62 ] ) HLAC ( 0302 , 030301 ) Zubrod Performance Scale ( PS ) 0 1 Creatinine &lt; 1.8 mg/dl Ejection fraction &gt; /=40 % Corrected Carbon Monoxide Diffusing Capacity ( DLCO ) &gt; /=45 % predict Serum bilirubin &lt; /=1.5 mg/dl due Gilbert 's syndrome Uncontrolled infection HIV , hepatitis B surface antigen hepatitis C seropositive serum glutamicpyruvic transaminase ( SGPT ) &gt; 200 IU/ml Pregnant lactate woman i.e. , positive Beta human chorionic gonadotrophin ( hCG ) test woman child bear potential . Child bear potential define postmenopausal 12 month previous surgical sterilization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Anti-Third Party Cytolytic Lymphocytes</keyword>
	<keyword>Indolent Lymphoid Malignancies</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludara</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan®</keyword>
	<keyword>Neosar®</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>T-lymphocytes</keyword>
	<keyword>Miltenyi CliniMACS System</keyword>
	<keyword>Graft v . Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Allogenic Transplant</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamycin</keyword>
</DOC>